Anamorelin HCl Market

The Anamorelin HCl market continues to grow, with a projected CAGR of about 9% over the forecast period. Anamorelin hydrochloride is an orally active ghrelin receptor agonist developed to treat cancer anorexia-cachexia syndrome (CACS), a complex metabolic condition characterized by involuntary weight loss, muscle atrophy, and reduced appetite, commonly observed in cancer patients, particularly those with non-small cell lung cancer (NSCLC)

The prevalence of cancer anorexia-cachexia syndrome varies around the globe, influencing the demand for medicines such as anamorelin. Developed regions with advanced healthcare infrastructures, such as North America and Europe, have greater CACS diagnosis and treatment rates, resulting in increasing use of medicines such as anamorelin. Emerging economies in Asia-Pacific and Latin America are also recognizing the necessity of dealing with CACS, with better healthcare systems and increased awareness driving market growth in these countries.

The Anamorelin HCl market report shows Anamorelin has been demonstrated to be beneficial in improving body weight, muscle mass, and appetite in cancer patients with cachexia, with clinical studies revealing significant gains in lean body mass and quality of life without serious side effects.  Anamorelin, marketed as Adlumiz, was licensed in Japan in January to treat cancer cachexia associated with non-small cell lung, stomach, pancreatic, and colorectal malignancies.  However, regulatory approval in other places, such as the EU, has been hampered by modest effects on lean body mass and no demonstrated benefit on handgrip strength or general quality of life.  With continuing research and pipeline treatments, the cancer anorexia-cachexia market is poised for significant development, promising better patient outcomes.